A test that costs less than a $1 and yields results in minutes has been shown in newly published studies to be more sensitive and more exact than the current standard test for early-stage prostate cancer.
The simple test developed by University of Central Florida scientist Qun “Treen” Huo holds the promise of earlier detection of one of the deadliest cancers among men. It would also reduce the number of unnecessary and invasive biopsies stemming from the less precise PSA test that’s now used.
“It’s fantastic,” said Dr. Inoel Rivera, a urologic oncologist at Florida Hospital Cancer Institute, which collaborated with Huo on the recent pilot studies. “It’s a simple test. It’s much better than the test we have right now, which is the PSA, and it’s cost-effective.”
When a cancerous tumor begins to develop, the body mobilizes to produce antibodies. Huo’s test detects that immune response using gold nanoparticles about 10,000 times smaller than a freckle.
When a few drops of blood serum from a finger prick are mixed with the gold nanoparticles, certain cancer biomarkers cling to the surface of the tiny particles, increasing their size and causing them to clump together.
Among researchers, gold nanoparticles are known for their extraordinary efficiency at absorbing and scattering light. Huo and her team at UCF’s NanoScience Technology Center developed a technique known as nanoparticle-enabled dynamic light scattering assay (NanoDLSay) to measure the size of the particles by analyzing the light they throw off. That size reveals whether a patient has prostate cancer and how advanced it may be.
And although it uses gold, the test is cheap. A small bottle of nanoparticles suspended in water costs about $250, and contains enough for about 2,500 tests.
“What’s different and unique about our technique is it’s a very simple process, and the material required for the test is less than $1,” Huo said. “And because it’s low-cost, we’re hoping most people can have this test in their doctor’s office. If we can catch this cancer in its early stages, the impact is going to be big.”
The Latest on: Prostate Cancer
via Google News
The Latest on: Prostate Cancer
- Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate canceron November 19, 2019 at 7:40 pm
Germline variants in androgen metabolism genes may influence clinical response to androgen deprivation therapy (ADT) in advanced prostate cancer. We sought to investigate the prognostic significance ...
- Hormone Refractory Prostate Cancer (HRPCA) Market To Reach USD 15.64 Billion By 2026| Reports And Dataon November 19, 2019 at 5:50 pm
New york, Nov. 19, 2019 (GLOBE NEWSWIRE) -- The global hormone refractory prostate cancer (HRPCA) market is forecast to reach USD 15.64 Billion by 2026, according to a new report by Reports and Data.
- Prostate cancer patients receiving care at MultiD clinic more likely to be advised about treatment choiceson November 19, 2019 at 9:46 am
Newly diagnosed prostate cancer patients have multiple standard-of-care treatment options available, but many are not fully informed of their choices. A study led by researchers at The University of ...
- Myovant's Stock Soars After Relugolix Aces Late-Stage Study For Prostate Canceron November 19, 2019 at 4:40 am
Myovant said the Phase 3 study dubbed HERO that evaluated once-daily oral relugolix 120mg in men with advanced prostate cancer met the primary efficacy endpoint, as well as six key secondary endpoints ...
- With prostate cancer trial done, Peninsula drug maker will ask for FDA approval early next yearon November 19, 2019 at 4:19 am
A Peninsula company that didn’t exist four years ago is on the cusp of asking regulators early next year to approve versions of its marquee drug against a debilitating condition in women as well as a ...
- A computer model has learned to detect prostate canceron November 19, 2019 at 4:19 am
According to Yuri Kistenev, in the analysis, artificial intelligence not only detects the presence of cancer cells, but also evaluates the tumor according to the Gleason score, which is traditionally ...
- Why Hasn’t Immunotherapy Been Working For Prostate Cancer? Bone Tumors May Be The Answeron November 18, 2019 at 4:00 pm
Researchers from MD Anderson in Texas have uncovered new clues as to why immunotherapy may fail in ... [+] many men with prostate cancer. Immunotherapy drugs called immune checkpoint inhibitors have ...
- A NF-ĸB-Activin A signaling axis enhances prostate cancer metastasison November 18, 2019 at 5:26 am
Metastasis is a main cause of death in prostate cancer (PCa). To dissect the molecular cues from cancer cell–microenvironment interaction that drive metastatic cascade, bone metastatic PCa cells were ...
- Omega-3 Protects Against Cardiovascular Illness-related Death Without Risk Of Prostate Canceron November 18, 2019 at 3:50 am
Their focus is centered on whether it impacts the risk of prostate cancer and heart health. During the 2019 American Heart Association Scientific Sessions held in Philadelphia on November 17, 2019, ...
- Omega-3 shows protection against heart disease-related death, without prostate cancer riskon November 18, 2019 at 12:12 am
That's why researchers at the Intermountain Healthcare Heart Institute continue to research the potential benefits and risks of this popular supplement, especially when it comes to prostate cancer ...
via Bing News